Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:583-587
Published online before print January 20, 2005, doi: 10.1161/01.STR.0000141936.36596.1e
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/3/583    most recent
01.STR.0000141936.36596.1ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naidech, A. M.
Right arrow Articles by Fitzsimmons, B.-F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naidech, A. M.
Right arrow Articles by Fitzsimmons, B.-F. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PHENYTOIN SODIUM
Related Collections
Right arrow Other Treatment
Right arrow Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage

(Stroke. 2005;36:583.)
© 2005 American Heart Association, Inc.


Original Contributions

Phenytoin Exposure Is Associated With Functional and Cognitive Disability After Subarachnoid Hemorrhage

Andrew M. Naidech, MD, MSPH; Kurt T. Kreiter, PhD; Nazli Janjua, MD; Noeleen Ostapkovich, MS; Augusto Parra, MD, MPH; Christopher Commichau, MD; E. Sander Connolly, MD; Stephan A. Mayer, MD Brian-Fred M. Fitzsimmons, MD

From the Departments of Neurology and Critical Care (A.M.N.), Northwestern University, Chicago, Ill; and the Department of Critical Care and Vascular Neurology (K.T.K., N.J., N.O., A.P., C.C., S.A.M., B.-F.M.F.) and Department of Neurosurgery (E.S.C.), Columbia University, New York, NY.

Correspondence to Dr Andrew M. Naidech, 710 N Lake Shore Dr, 14th floor, Chicago, IL 60614. E-mail a-naidech{at}northwestern.edu

Background and Purpose— Phenytoin (PHT) is routinely used for seizure prophylaxis after subarachnoid hemorrhage (SAH), but may adversely affect neurologic and cognitive recovery.

Methods— We studied 527 SAH patients and calculated a "PHT burden" for each by multiplying the average serum level of PHT by the time in days between the first and last measurements, up to a maximum of 14 days from ictus. Functional outcome at 14 days and 3 months was measured with the modified Rankin scale, with poor functional outcome defined as dependence or worse (modified Rankin Scale ≥4). We assessed cognitive outcomes at 14 days and 3 months with the telephone interview for cognitive status.

Results— PHT burden was associated with poor functional outcome at 14 days (OR, 1.5 per quartile; 95% CI, 1.3 to 1.8; P<0.001), although not at 3 months (P=0.09); the effect remained (OR, 1.6 per quartile; 95% CI, 1.2 to 2.1; P<0.001) after correction for admission Glasgow Coma Scale, fever, stroke, age, National Institutes of Health Stroke Scale ≥10, hydrocephalus, clinical vasospasm, and aneurysm rebleeding. Seizure in hospital (OR, 4.1; 95% CI, 1.5 to 11.1; P=0.002) was associated with functional disability in a univariate model only. Higher quartiles of PHT burden were associated with worse telephone interview for cognitive status scores at hospital discharge (P<0.001) and at 3 months (P=0.003).

Conclusions— Among patients treated with PHT, burden of exposure to PHT predicts poor neurologic and cognitive outcome after SAH.


Key Words: critical care • phenytoin • subarachnoid hemorrhage




This article has been cited by other articles:


Home page
StrokeHome page
J. B. Bederson, E. S. Connolly Jr, H. H. Batjer, R. G. Dacey, J. E. Dion, M. N. Diringer, J. E. Duldner Jr, R. E. Harbaugh, A. B. Patel, and R. H. Rosenwasser
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association
Stroke, March 1, 2009; 40(3): 994 - 1025.
[Full Text] [PDF]


Home page
StrokeHome page
G. J. Redekop
Prognostic Factors and Targets for Intervention After Subarachnoid Hemorrhage
Stroke, August 1, 2007; 38(8): 2217 - 2218.
[Full Text] [PDF]


Home page
StrokeHome page
J. I. Suarez
Timing of Neuropsychological Outcome Measures in Patients With Subarachnoid Hemorrhage
Stroke, June 1, 2007; 38(6): 1724 - 1725.
[Full Text] [PDF]


Home page
NeurologyHome page
P. Ryvlin, A. Montavont, and N. Nighoghossian
Optimizing therapy of seizures in stroke patients
Neurology, December 26, 2006; 67(12_suppl_4): S3 - S9.
[Abstract] [Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A M Naidech, J Drescher, P Tamul, A Shaibani, H H Batjer, and M J Alberts
Acute physiological derangement is associated with early radiographic cerebral infarction after subarachnoid haemorrhage
J. Neurol. Neurosurg. Psychiatry, December 1, 2006; 77(12): 1340 - 1344.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. K.C. Wong, W. S. Poon, and A. M. Naidech
Use of Phenytoin and Other Anticonvulsant Prophylaxis in Patients With Aneurysmal Subarachnoid Hemorrhage * Response:
Stroke, December 1, 2005; 36(12): 2532 - 2532.
[Full Text] [PDF]


Home page
StrokeHome page
S. Koch, B. E. Gidal, and A. M. Naidech
Phenytoin and Cognitive Decline * Response:
Stroke, October 1, 2005; 36(10): 2070 - 2071.
[Full Text] [PDF]